ArticleJournal of skin cancer2011
Basal cell carcinoma: from the molecular understanding of the pathogenesis to targeted therapy of progressive disease.
Article in Journal of skin cancer, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study.BMC cancer · 2017Trial
- Safety and efficacy of vismodegib in patients with basal cell carcinoma nevus syndrome: pooled analysis of two trials.Orphanet journal of rare diseases · 2016Trial
- Clinical benefit assessment of vismodegib therapy in patients with advanced basal cell carcinoma.The oncologist · 2014Trial
- Basal Cell Nevus Syndrome and Sporadic Basal Cell Carcinoma: A Comparative Study of Clinicopathological Features.Acta dermato-venereologica · 2025Article
- Skin Development and Disease: A Molecular Perspective.Current issues in molecular biology · 2024Review
- Epidemiology and tumor microenvironment of ocular surface and orbital tumors on growth and malignant transformation.Frontiers in oncology · 2024Review
- Immunohistochemical Analysis of Single-Stranded DNA Binding Protein 2 in Non-Melanoma Skin Cancers.Biomedicines · 2023Article
- Effectiveness, Safety and Utilization of Vismodegib for Locally Advanced Basal Cell Carcinoma Under Real-world Conditions: Non-interventional Cohort Study JONAS.Acta dermato-venereologica · 2022Article
- Real-world assessment and treatment of locally advanced basal cell carcinoma: Findings from the RegiSONIC disease registry.PloS one · 2022Article
- Article
- Genome-Wide Expression Difference of MicroRNAs in Basal Cell Carcinoma.Journal of immunology research · 2021Article
- Evaluation of Patched-1 Protein Expression Level in Low Risk and High Risk Basal Cell Carcinoma Subtypes.Asian Pacific journal of cancer prevention : APJCP · 2019Article
- Development of Multiple-Lesion Basal Cell Carcinoma of the Skin: A Comprehensive Review.Sisli Etfal Hastanesi tip bulteni · 2019Review
- Safety and efficacy of vismodegib in patients aged ≥65 years with advanced basal cell carcinoma.Oncotarget · 2016Article
- The activity and tissue distribution of thioredoxin reductase in basal cell carcinoma.Journal of cancer research and clinical oncology · 2016Article
- Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma.The oncologist · 2016Review
- Metallothionein 3 expression in normal skin and malignant skin lesions.Pathology oncology research : POR · 2015Article
- Clinical and genetic characterization of basal cell carcinoma and breast cancer in a single patient.SpringerPlus · 2014Article
- Met, IGF1R, and other new targets in upper GI malignancies.Current treatment options in oncology · 2013Article
- Advanced basal cell carcinoma.Wiener medizinische Wochenschrift (1946) · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Due to intensified research over the past decade, the Hedgehog (HH) pathway has been identified as a pivotal defect implicated in roughly 25% of all cancers. As one of the most frequent cancer worldwide, the development of Basal cell carcinoma (BCC) due to activation of the HH pathway has been convincingly demonstrated. Thus the discovery of this central tumor-promoting signalling pathway has not only revolutionized the understanding of BCC carcinogenesis but has also enabled the development of a completely novel therapeutic approach. Targeting just a few of several potential mutations, HH inhibitors such as GDC-0449 achieved already the first promising results in metastatic or locally advanced BCC. This paper summarizes the current understanding of BCC carcinogenesis and describes the current "mechanism-based" therapeutic strategies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.